Real-world safety assessment of avacopan in patients with antineutrophil cytoplasmic antibody-associated vasculitis - PubMed
4 hours ago
- #Avacopan Safety
- #AAV Treatment
- #Real-World Evidence
- Study assessed real-world safety of avacopan in AAV patients using FDA Adverse Event Reporting System data.
- Identified 3150 adverse event reports with 8 significant system-level and 92 specific signals, including 34 new events.
- Median time to onset was 48 days, overall pattern suggested early failure, and age ≥65 increased cumulative incidence risk.
- Hepatobiliary events were most common, especially in female and elderly patients (≥65 years old).
- Conclusion: Avacopan showed favorable safety overall, but age and specific event risks call for individualized monitoring.